Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan on October 1, 2024 Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu–PSMA–I&T and 64Cu–PSMA–I&TBuilds on long–standing [...] Read more »